AN2 Therapeutics (ANTX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 3, 2026, with voting on director elections and auditor ratification.

• Stockholders of record as of April 15, 2026, are eligible to vote, with options to vote online, by phone, or by mail.

• Proxy materials are distributed primarily online to expedite delivery and reduce costs.

Voting matters and shareholder proposals

• Stockholders will vote on electing three Class I directors (Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.) for terms expiring in 2029.

• Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026 is on the agenda.

• Board recommends voting FOR all nominees and auditor ratification.

• Proposals for the 2027 annual meeting must be submitted by December 23, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of nine members divided into three staggered classes, with detailed biographies and qualifications provided for each director.

• Majority of directors are independent under Nasdaq rules; only the CEO is not independent.

• Board leadership includes a chair (CEO) and a lead independent director.

• Board committees include audit, compensation, and nominating/governance, each with defined charters and independent membership.

• All directors attended at least 75% of meetings in 2025.